The present study is conducted with the formulation and optimization of lipid-polymer hybrid nanoparticles that could effectively deliver siRNA to silence mutant p53 in a mouse osteosarcoma cell line 318–1 with minimal cytotoxicity. The gene discussed is TP53; the disease is osteosarcoma.